Poster-Disease-modifying Therapy

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

DMT33

Heinz Wiendl, MD, Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands, Klaus Schmierer, MD, PhD, The Blizard Institute (Neuroscience), Queen Mary University of London, London, United Kingdom, Suzanne Hodgkinson, MD, Immune Tolerance Group, Ingham Institute for Applied Medical Research, UNSW Medicine, Liverpool, Australia, Tobias Derfuss, MD, Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland, Andrew Chan, MD, Ambulantes Neurozentrum, Inselspital, Bern, Switzerland, Finn Sellebjerg, MD, Department of Neurology, Multiple sclerosis & Neuroimmunology Division, University of Texas Southwestern Medical Center, Dallas, TX, Anat Achiron, MD, PhD, Sheba Medical Center, Ramat Gan, Israel, Xavier Montalban, MD, PhD, Division of Neurology, St Michaels Hospital, University of Toronto, Toronto, ON, Canada, Alexandre Prat, MD, Department of Neurosciences, Université de Montréal, Montréal, QC, Canada, Nicola De Stefano, MD, PhD, University of Siena, Siena, Italy, Frederik Barkhof, MD, PhD, Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom; Department of Radiology, VU University Medical Center, Amsterdam, Netherlands, Letizia Leocani, MD, Ospedale San Raffaele, Milano, Italy, Patrick Vermersch, PhD, University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent, Lille, France, Anita Chudecka, MA, Cytel, Inc., Cambridge, MA, Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland and Ursula Boschert, PhD, Merck KGaA, Darmstadt, Germany, Eysins, Switzerland

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with multiple sclerosis (MS). Objectives: To report on peripheral immune cell subset dynamics and immunoglobulin levels in the first 12 months of CladT therapy. Methods: Longitudinal evaluation of peripheral blood immune cells in patients receiving CladT in a sub-study of MAGNIFY-MS (NCT03364036). Absolute cell counts and percent change from baseline were assessed for adaptive immune cell subtypes and immunoglobulins. Immunophenotyping was completed at baseline and months 1, 2, 3, 6, and 12. Results: Full analysis set: 57 patients (median age 37 years; 61% female; ?2 relapses in previous year, 70%). Effector and regulatory B cells were reduced from Month 1 and showed a subtype-specific repopulation pattern. Change from baseline for CD19+ B cells: Month 1, -77%; Month 2, -90%; Month 12, -35%. Memory B cells: Month 1, -74%; Month 3, -93%; Month 12,-87%. Plasmablasts: Month 1, -28%; Month 3, -78%; Month 12, -51%. Regulatory B cells (CD19+, CD24bright, and CD38bright): Month 1, -45%; Month 3, +176%; Month 6, +171%; Month 12, +50%. Naïve/transitional B cells: Month 1, -79%/-61%; Month 3, -69%/+35%; Month 12, +35%/+23%. Decrease in T cell subsets was moderate and slower, nadir occurring between 3 and 6 months. T-helper 17 CD4+ and terminally differentiated effector memory CD8+ T cell counts reached nadir at Month 3 (-35% and -25%, respectively). No clinically meaningful change in serum IgG or IgM was observed over 12 months. Conclusions: Assessment of lymphocyte dynamics following CladT over 1 year demonstrates that effects occur from Month 1, and are sustained in several immune cell subpopulations. CladT exerts a pronounced effect on memory B cells, while immunoglobulin levels are unaffected over 12 months. Results suggest early onset of CladT action, underpinned by MAGNIFY-MS MRI results, may be mediated through this specific pattern of sustained decrease and reconstitution of B and T cell subtypes in a highly active MS population.

[learn_press_profile]

2021 CMSC Annual Meeting

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

DMT33

MAILING ADDRESS

CONTACT US

FOLLOW US